Cardio Diagnostics
Get Started

Who We Serve

PatientsProvidersEmployers

Our Solutions

OverviewEpi+Gen CHD™PrecisionCHD™HeartRisk™CardioInnovate360™

Company

About UsAbout CVDCareersTechnologyResourcesContact Us

Investors

Stock InformationSEC FilingsPress ReleasesPresentationsEmail SubscriptionCorporate GovernanceContact Investor Relations
Contact Us

2026 Cardio Diagnostics, Inc.

Privacy PolicyTerms of UseHIPAA Notice

The Cardio Diagnostics clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical laboratory testing. The Epi+Gen CHD™ and PrecisionCHD™ tests were developed, and their performance characteristics were determined by Cardio Diagnostics. These tests should be ordered by a licensed healthcare provider, and test results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms, and other relevant clinical information. These tests are intended for clinical purposes and have not been cleared or approved by the U.S. Food and Drug Administration (FDA).

For the Epi+Gen CHD™ test, a lower risk result does not eliminate the possibility of a coronary heart disease event occurring or that coronary heart disease is present, and a higher risk result does not imply a diagnosis of coronary heart disease or that a coronary heart disease event will occur. For the PrecisionCHD™ test, a "Signal Detected" result is not a diagnosis of coronary heart disease, and a "Signal Not Detected" result does not eliminate the possibility that coronary heart disease is present or could occur in the future. False positive and false negative test results do occur. Rx only.

In addition to a federal CLIA license, the Cardio Diagnostics clinical laboratory holds active state clinical laboratory licenses in California, Maryland, Pennsylvania, and Rhode Island. The laboratory is not currently licensed to process patient samples originating from the state of New York.

Hero Background

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026
Print item:Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026  View PDF item:Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026

CHICAGO - Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time.

The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, ongoing and planned studies, reimbursement progress, and strategic growth initiatives.

Webcast and Conference Call Details

Date: Thursday, August 20, 2026
Time: 3 p.m. Central Time
Webcast: https://www.cstproxy.com/cardiodiagnosticsinc/investorday/2026/aug/

To access the conference call by telephone, U.S. and Canada-based callers should dial 1 800-450-7155 (toll-free), and callers from outside the U.S. and Canada should dial +1 857-999-9155 (standard rates apply). Participants should use the passcode provided below to join.

Passcode: 4543643#

A replay of the webcast will be available via the webcast link above following the conclusion of the call.

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ("Core Technology") for cardiovascular disease. For more information, please visit https://cdio.ai/.

Forward-Looking Statements

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will," "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, and dependence on results as discussed in the Annual Report on Form 10-K for the period ended December 31, 2025, under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260805019123/en/

Contacts

Investors
Investor Relations
855-226-9991
[email protected]

8/5/2026 8:35:00 AM